Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
Lindén O, Tennvall J, Hindorf C, Cavallin-Ståhl E, Lindner KJ, Ohlsson T, Wingårdh K, Strand SE. Lindén O, et al. Acta Oncol. 2002;41(3):297-303. doi: 10.1080/02841860260088854. Acta Oncol. 2002. PMID: 12195750
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J. Lindén O, et al. Clin Cancer Res. 2005 Jul 15;11(14):5215-22. doi: 10.1158/1078-0432.CCR-05-0172. Clin Cancer Res. 2005. PMID: 16033839 Clinical Trial.
61 results
Jump to page
Feedback